Kidney Cancer Weekly

July 13, 2026

Videos

Peer-to-Peer Clinical Conversations

LITESPARK-033 and the Development of Belzutifan plus Zanzalintinib in Kidney Cancer - Cristina Suárez

Cristina Suárez

Cristina Suárez describes LITESPARK-033, a phase 3 trial addressing an unmet need in patients who progress during or within 24 months after adjuvant pembrolizumab for clear cell renal cell carcinoma.

View

Restricted Mean Survival Time Analysis of First-Line IO Combinations in Advanced RCC - Yudai Ishiyama

Yudai Ishiyama

Yudai Ishiyama presents a restricted mean survival time analysis of four IO combination regimens in advanced clear cell RCC.

View

Beyond the Abstracts

Ablative Techniques in Renal Tumours for Inoperable Patients: Step Forward in SBRT - Beyond the Abstract

Titrating Cabozantinib in Metastatic Renal Cell Carcinoma Patients Using Goldilocks Principle: A Real-World Evidence Study - Beyond the Abstract

Conference Coverage

ASCO 2026: Phase 3 Study to Assess the Safety and Efficacy of 177Lu-Girentuximab in Advanced, Relapsed, or Recurrent ccRCC (LUTEON)

AUA 2026: Development and Internal Validation of a Novel Prognostic Score for Real-world Renal Cell Carcinoma Patients Eligible for Adjuvant therapy

EAU 2026: Adjuvant Pembrolizumab + Belzutifan for Clear Cell RCC: Primary and Exploratory Efficacy Outcomes from the Phase 3 LITESPARK-022 Study

SES AUA 2026: Impact of Cytoreductive Nephrectomy for RCC with Tumor Thrombus: Results from the Intercontinental Collaboration of RCC

Articles

Editor Selected Abstracts and Commentaries

Renal Cancer

Robotic partial nephrectomy is inching toward the gold standard for small renal masses-a narrative review.

De-escalation of Treatment in Metastatic Renal Cell Carcinoma: Why? How? Who? When?

Navigating Recurrence in Clear Cell Renal Cell Carcinoma after Adjuvant Immunotherapy.

Multimodal imaging to analyze the biomechanical properties of kidney tumors, evaluating feasibility, inter-modality correspondence, and diagnostic value (UroCCR-115).

Post-treatment renal function deterioration following radiation therapy: implications for SABR in primary renal cell cancer.

Incidence and Impact of Pseudoprogression and Mixed Responses in Metastatic Renal Cell Carcinoma Patients Treated with Ipilimumab/Nivolumab: A Retrospective Analysis - Beyond the Abstract

Peripheral B-cell receptor repertoire predicts immune-related adverse events following immune checkpoint inhibitor therapy in advanced renal cell carcinoma.

Sutureless Purely Off-clamp Robotic Partial Nephrectomy: Evidence from a Randomized Controlled Noninferiority Trial - Beyond the Abstract

Evaluation and analysis of renal injury in patients with advanced renal cell carcinoma receiving first-line benmelstobart plus anlotinib: results from the ETER100 study.

A Core Outcome Set for Localized Renal Cell Cancer (L-RCC-COS).

Sarcopenia is associated with poor survival among patients with non-metastatic renal cell carcinoma and venous tumor thrombus.

Investigating the determinants of immunotherapy response in the primary tumour of clear cell renal cell carcinoma (RCC).

CONNECT WITH US

Questions or Comments? Email us at

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Kidney Cancer Weekly

Renal Cancer

Login